SLZ0 Stock Chart & Stats
€4.67
€0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range€4.67 - €4.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€4.58M
Enterprise Value-€4.13M
Total Cash (Recent Filing)€4.91M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.84
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-272.82
Revenue Forecast (FY)€8.66M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving essentially no debt reduces structural insolvency and interest burden, an enduring strength for a pre-revenue biotech. This lowers fixed financing costs, preserves cash runway for R&D, and improves flexibility to negotiate non-dilutive partnerships or staged financings tied to milestones.
Focused R&D StrategyA clear scientific focus on neuroplastogenic small molecules and CNS indications builds durable R&D specialization. This concentration supports deep domain expertise, targeted clinical development paths, and potential first-mover or niche advantages in psychedelics-inspired therapeutics across anxiety and depression indications.
Strengthened Incentive AlignmentImplementing multi-year vesting and change-in-control provisions aligns management with long-term clinical and shareholder outcomes. This governance enhancement reduces short-termism, improves retention through multi-year trials, and better ties executive rewards to durable value-creation milestones common in biotech.
Bears Say
No Revenue; Sustained LossesAbsence of revenue and sizable recurring losses mean the company cannot self-fund development long-term. Persistent operating deficits elevate execution risk, force dependence on external capital or partnerships, and create potential program delays if financing is constrained before clinical value is realized.
High Cash BurnSustained negative operating and free cash flow erode runway and make strategic planning dependent on new funding. Continued burn pressures management to prioritize programs, may necessitate dilutive financings, and increases execution risk for multi-year clinical plans without firm non-dilutive revenue sources.
Reliance On Equity RaisesFrequent use of at-the-market equity offerings signals ongoing capital needs and likely future dilution. Reliance on public equity markets reduces strategic flexibility, can alter investor ownership long-term, and indicates limited internal liquidity to sustain clinical development without continued external financing.
Enveric Biosciences News
SLZ0 FAQ
What was Enveric Biosciences, Inc.’s price range in the past 12 months?
Enveric Biosciences, Inc. lowest stock price was €4.67 and its highest was €4.79 in the past 12 months.
What is Enveric Biosciences, Inc.’s market cap?
Enveric Biosciences, Inc.’s market cap is €4.58M.
When is Enveric Biosciences, Inc.’s upcoming earnings report date?
Enveric Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 49 days.
How were Enveric Biosciences, Inc.’s earnings last quarter?
Enveric Biosciences, Inc. released its earnings results on May 15, 2026. The company reported -€0.95 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.95.
Is Enveric Biosciences, Inc. overvalued?
According to Wall Street analysts Enveric Biosciences, Inc.’s price is currently Undervalued.
Does Enveric Biosciences, Inc. pay dividends?
Enveric Biosciences, Inc. does not currently pay dividends.
What is Enveric Biosciences, Inc.’s EPS estimate?
Enveric Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences, Inc. have?
Enveric Biosciences, Inc. has 3,681,884 shares outstanding.
What happened to Enveric Biosciences, Inc.’s price movement after its last earnings report?
Enveric Biosciences, Inc. reported an EPS of -€0.95 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enveric Biosciences, Inc.?
Currently, no hedge funds are holding shares in DE:SLZ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences, Inc.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Options Prices
Currently, No data available
---